Topical Trametinib for Agminated Spitz Nevi Harboring HRAS Mutation

Document Type

Journal Article

Publication Date

2-19-2025

Journal

Pediatric dermatology

DOI

10.1111/pde.15903

Keywords

agminated spitz nevus; dermatology; male; nevus spilus; skin diseases

Abstract

The treatment of agminated Spitz nevi can be challenging due to the potential for disfigurement in cosmetically sensitive areas. We report the case of a pediatric patient with progressive agminated Spitz nevi arising from a nevus spilus on the face with an associated pathogenic HRAS p.G13R mutation revealed on next-generation sequencing (NGS). The patient was treated with compounded topical trametinib 1% cream and demonstrated significant clinical improvement following 12 weeks of twice-daily treatment. Our case highlights the potential role of MEK inhibition as a targeted, non-surgical treatment for HRAS-mutated agminated Spitz nevi and adds to the growing understanding of their genetic etiology.

Department

School of Medicine and Health Sciences Student Works

Share

COinS